Q32 Bio (QTTB) Liabilities and Shareholders Equity (2017 - 2026)

Q32 Bio's Liabilities and Shareholders Equity history runs 10 years deep, the most recent figure standing at $63.7 million for Q1 2026.

• On a quarterly basis, Liabilities and Shareholders Equity fell 19.47% year-over-year to $63.7 million in Q1 2026; TTM through Mar 2026 was $249.4 million, a 37.69% decrease from a year earlier, with the FY2025 full-year figure at $61.8 million, down 33.09% from the prior year.
• Liabilities and Shareholders Equity advanced to $63.7 million in Q1 2026 per QTTB's latest filing, from $61.8 million in the prior quarter.
• Across five years, Liabilities and Shareholders Equity topped out at $311.0 million in Q1 2022 and bottomed at $47.1 million in Q4 2023.
• The 5-year median for Liabilities and Shareholders Equity is $124.2 million (2024), against an average of $143.7 million.
• Across the five-year window, Liabilities and Shareholders Equity sank 79.4% in 2023 and jumped 96.21% in 2024, its largest moves.
• Year by year, Liabilities and Shareholders Equity stood at $228.5 million in 2022, then sank by 79.4% to $47.1 million in 2023, then surged by 96.21% to $92.3 million in 2024, then sank by 33.09% to $61.8 million in 2025, then climbed by 3.07% to $63.7 million in 2026.
• Per Business Quant, the three latest QTTB Liabilities and Shareholders Equity figures stand at $63.7 million (Q1 2026), $61.8 million (Q4 2025), and $57.8 million (Q3 2025).